Press Release: Sanofi “all in” on artificial intelligence and data science to speed breakthroughs for patients
13 Giugno 2023 - 2:00PM
Sanofi “all in” on artificial intelligence and
data science to speed breakthroughs for patients
Paris, June
13, 2023. Sanofi
takes the next step in its company-wide digital transformation and
rolls-out plai at scale. plai, Sanofi’s industry-leading app
developed with artificial intelligence (AI) platform company
Aily Labs, delivers real-time, reactive data
interactions and gives an unprecedented 360° view across all Sanofi
activities. The app aggregates available company internal data
across functions and harnesses the power of AI to provide timely
insights and personalized “what if” scenarios to support thousands
of Sanofi teams decision makers to take informed decisions in a
simple and modern digital user experience.
Paul HudsonCEO, Sanofi“Our
ambition is to become the first pharma company powered by
artificial intelligence at scale, giving our people tools and
technologies that focus on insights and allow them to make better
everyday decisions. The use of artificial intelligence and data
science already support our teams’ efforts in areas such as
accelerating drug discovery, enhanced clinical trial design, and
improving manufacturing and supply of medicines and vaccines. We
have just scratched the surface as to how we embrace these
disruptive technologies to achieve our ambition of transforming the
practice of medicine.”
plai is an essential enabler in the company-wide
digital transformation and data democratisation journey. AI-powered
tools help Sanofi teams make better and faster data-driven
decisions, hence boosting productivity across the value chain: from
research to clinical operations to manufacturing and supply to
business analysis.
In Research,
Sanofi has built multiple AI programs to slash research times
through improved predictive modelling and automate time-sink
activities. As a result, AI enables R&D teams to scale and
accelerate ground-breaking research processes from a matter of
weeks to just hours and improve potential target identification in
therapeutic areas like immunology, oncology or neurology by 20 to
30%.AI also accelerates work on mRNA research. For an mRNA vaccine
to reach its designated cells and produce disease-fighting
proteins, it must be carried by a stable drug delivery system via a
special particle, known as a lipid nanoparticle. While Sanofi owns
a large library of lipid nanoparticles, R&D teams now use AI to
create digital models to predict the strongest selection of
particles. It increased the speed of the lipid nanoparticle
prediction process from months to days.
In Clinical operations, the
increasing digitization and leverage of plai’s insights empower
Sanofi teams to rethink how to run better clinical trials. For
example, R&D teams can find and set up new, more convenient
trial sites for their target groups, broadening opportunities for
those from historically underrepresented communities to participate
in clinical research. With improved representation, Sanofi
continues its work toward a future where all trials reflect the
diversity of the people most affected by the diseases studied.
In Manufacturing and
Supply, Sanofi is digitizing quality
assessment processes, moving from paper to Electronic Batch
Records, leveraging digital and data to improve asset
utilization and increase productivity by
implementing new manufacturing 4.0 capabilities.
Sanofi has also developed an in-house AI-enabled yield
optimization solution which learns from past and current batch
performance to enable consistently higher yield levels.
This helps to optimize usage of raw materials, contributing to the
company’s environmental objectives, and supports improved cost
efficiency. Also, recent plai adoption within Sanofi's biopharma
Supply Chain has proven the ability to predict 80% of low inventory
positions, allowing teams to take mitigating actions to secure
supply, faster than ever before.
Best-in-class technological collaborations to
speed scientific breakthroughs for patients
In 2022 Sanofi acquired Amunix
Pharmaceuticals, which uses AI to tailor-deliver
medicines that become active only in tumor tissues, while not
harming normal ones. The same year, Sanofi joined forces in a
collaboration with pioneering biotech Exscientia
to explore new treatments for cancer and diseases linked to the
immune system. Using Exscientia’s AI-based capabilities and
personalized medicine platform, Sanofi’s scientists can test drug
candidates against actual human tissue models, years before a
clinical trial. Also in 2022, Sanofi partnered with pharmaceutical
companies Insilico Medicine and
Atomwise to speed up medicine development using
their AI-driven platforms. This comes on top of Sanofi’s
partnership with Owkin in 2021, whose AI-driven
platform uses patient data from different medical centers to build
models and predict patient responses to treatments.
Sanofi @ Vivatech
Sanofi is a partner of VivaTech, Europe's
largest tech and startup event, taking place in Paris from June 14
to June 17, 2023. This year, Sanofi's digital experts
and 17 partner startups
specializing in data and e-health will show how AI and
Data can push the boundaries of science. Sanofi will notably
present its new groundbreaking partnership with French startup
Hillo to adapt its digital twin AI solution to
Sanofi's connected insulin pens. With this digital twin, the
influence of the diabetic patient's lifestyle or therapeutic habits
can now be taken into account in an optimized way.
Sanofi’s Consumer Healthcare business unit will
present its recently launched Open Innovation
Portal, which allows the wider supply chain community to
submit their solutions to unmet challenges in consumer health.
Startups, entrepreneurs, research institutions, accelerators,
universities and more will now be able to respond online to
challenge areas that have been identified by Sanofi Consumer
Healthcare, from creating sustainable packaging to developing new
products and technologies. The launch of the Sanofi Consumer
Healthcare Open Innovation Portal will facilitate the innovation of
the very best self-care solutions by uniting the boldest and
brightest external ideas with Sanofi’s expertise, infrastructure,
scale and reach. Sanofi will continue to add new challenges to the
Open Innovation Portal in the areas of digestive wellness, cough,
cold and flu, physical and mental wellness, allergy, pain care,
personal care and sustainability. Successful submissions will be
given the opportunity to drive innovation forward together as
collaborative partners on projects with Consumer Healthcare at
Sanofi. Innovators can visit https://www.innovation-sanofichc.com
to learn more and submit their ideas.
About SanofiWe are an innovative global
healthcare company, driven by one purpose: we chase the miracles of
science to improve people’s lives. Our team, across some 100
countries, is dedicated to transforming the practice of medicine by
working to turn the impossible into the possible. We provide
potentially life-changing treatment options and life-saving vaccine
protection to millions of people globally, while putting
sustainability and social responsibility at the center of our
ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Media RelationsSandrine
Guendoul | + 33 6 25 09 14 25
| sandrine.guendoul@sanofi.comNicolas
Obrist | + 33 6 77 21 27 55
| nicolas.obrist@sanofi.comVictor
Rouault | + 33 6 70 93 71 40
| victor.rouault@sanofi.comSally
Bain | + 1 617 834 6026
| sally.bain@sanofi.comEvan Berland | +1 215
432 0234 | evan.berland@sanofi.comChrystel
Baude | + 33 6 70 98 70 59
| chrystel.baude@sanofi.com
Investor RelationsEva
Schaefer-Jansen | + 33 7 86 80 56 39
| eva.schaefer-jansen@sanofi.comArnaud
Delépine | + 33 6 73 69
36 93 | arnaud.delepine@sanofi.comCorentine
Driancourt | + 33 6 40 56 92 21 |
corentine.driancourt@sanofi.comTarik Elgoutni | +
1 617 710 3587 | tarik.elgoutni@sanofi.comFelix
Lauscher | + 1 908 612 7239 |
felix.lauscher@sanofi.comNathalie
Pham | + 33 7 85 93 30 17 |
nathalie.pham@sanofi.com
Grafico Azioni Sanofi (EU:SAN)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Sanofi (EU:SAN)
Storico
Da Lug 2023 a Lug 2024